Therapeutic combinations and methods including IRM compounds
Assignee3M Innovative Properties Company
InventorsMark A. Tomai, Gary W. Gullikson, David M. Hammerbeck, Elaine A. Egging, Michael J. Reiter, Christopher D. Gram, John P. Vasilakos
Life of this patent
Estimating the term…
Abstract
The present invention provides therapeutic combinations that include an immune response modifier (IRM) component and an anti-inflammatory component. The inventions further provide methods of treating a condition by administering to one having the condition a therapeutic combination that includes an IRM component and an anti-inflammatory component.
Claims13
A method of treating neoplastic tumors, comprising administering to a subject having the neoplastic tumors a therapeutic combination that comprises
- (a) an IRM compound agonist of at least one of TLR7 or TLR8 in an amount effective to treat the neoplastic tumors, where the IRM compound comprises an imidazoquinoline amine, a tetrahydroimidazoquinoline amine, an imidazopyridine amine, a 1,2-bridged imidazoquinoline amine, a 6,7-fused cycloalkylimidazopyridine amine, an imidazonaphthyridine amine, a tetrahydroimidazonaphthyridine amine, an oxazoloquinoline amine, a thiazoloquinoline amine, an oxazolopyridine amine, a thiazolopyridine amine, an oxazolonaphthyridine amine, or a thiazolonaphthyridine amine;
- and
- (b) an anti-inflammatory compound in an amount effective to limit a side effect of administering the IRM compound, wherein the anti-inflammatory compound comprises a glucocorticoid.
A method of treating neoplastic tumors, comprising administering to a subject having the neoplastic tumors a therapeutic combination that comprises
- (a) an IRM compound agonist of at least one of TLR7 or TLR8 in an amount effective to treat the neoplastic tumors, where the IRM compound comprises a substituted imidazoquinoline amine, a tetrahydroimidazoquinoline amine, an imidazopyridine amine, a 1,2-bridged imidazoquinoline amine, a 6,7-fused cycloalkylimidazopyridine amine, an imidazonaphthyridine amine, a tetrahydroimidazonaphthyridine amine, an oxazoloquinoline amine, a thiazoloquinoline amine, an oxazolopyridine amine, a thiazolopyridine amine, an oxazolonaphthyridine amine, or a thiazolonaphthyridine amine;
- and
- (b) an anti-inflammatory compound in an amount effective to limit a side effect of administering the IRM compound,
- wherein the substituted imidazoquinoline amine is a amide substituted imidazoquinoline amine, sulfonamide substituted imidazoquinoline amine, urea substituted imidazoquinoline amine, aryl ether substituted imidazoquinoline amine, heterocyclic ether substituted imidazoquinoline amine, amido ether substituted imidazoquinoline amine, sulfonamido ether substituted imidazoquinoline amine, urea substituted imidazoquinoline ether, thioether substituted imidazoquinoline amine, or a 6-, 7-, 8-, or 9-aryl, heteroaryl, aryloxy or arylalkyleneoxy substituted imidazoquinoline amine.
A method of treating warts, basal cell carcinoma or actinic keratosis, comprising administering to a subject having the warts, basal cell carcinoma or actinic keratosis a therapeutic combination that comprises
- (a) an IRM compound agonist of at least one of TLR7 or TLR8 in an amount effective to treat the warts, basal cell carcinoma or actinic keratosis, where the IRM compound comprises an imidazoquinoline amine, a tetrahydroimidazoquinoline amine, an imidazopyridine amine, a 1,2-bridged imidazoquinoline amine, a 6,7-fused cycloalkylimidazopyridine amine, an imidazonaphthyridine amine, a tetrahydroimidazonaphthyridine amine, an oxazoloquinoline amine, a thiazoloquinoline amine, an oxazolopyridine amine, a thiazolopyridine amine, an oxazolonaphthyridine amine, or a thiazolonaphthyridine amine;
- and
- (b) an anti-inflammatory compound in an amount effective to limit a side effect of administering the IRM compound.
Dependencies are inferred from the claim text.